Agree we need to license out PCa test and HIV (even if only combo or certain regions). This should be able to provide more than enough upfront payments to finish cancer trials and build commercialization team (if clinical trials prove pre-clinical data).

I know our financials are not pretty, Paulson churners, and the current cancer data for leronlimab is only pre-clinical, but I would still think that some value would be given to the share price for the massive cancer potential....especially with RPs research, Maraviroc already proven in clinical trials (with much worse safety profile), etc. I am probably a little more confident than I should be for cancer working, but every indication thus far makes it very promising. If cancer doesn’t work, HIV still has potential for a large revenues, but would be more difficult to gain market share than cancer since we will have to steal most mono patients from the large pharmaceuticals and they likely won’t go down without a fight. I feel strongly that 2019 is going to end up being a great year for CYDY longs!!